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Background: Previous studies have revealed associations between psychiatric disorder
diagnosis and shorter telomere length. Here, we attempt to discern whether genetic risk
for psychiatric disorders, or use of pharmacological treatments (i.e., antidepressants),
predict shorter telomere length and risk for aging-related disease in a United Kingdom
population sample.
Methods: DNA samples from blood were available from 351 participants who were
recruited as part of the South East London Community Health (SELCoH) Study,
and for which whole-genome genotype data was available. Leukocyte telomere
length was characterized using quantitative polymerase chain reactions. Individualized
polygenic risk scores for major depressive disorder (MDD), bipolar disorder (BD),
and schizophrenia (SCZ) were calculated using Psychiatric Genomics Consortium
summary statistics. We subsequently performed linear models, to discern the impact
polygenic risk for psychiatric disorders (an etiological risk factor) and antidepressant use
(common pharmacological treatment) have on telomere length, whilst accounting for
other lifestyle/health factors (e.g., BMI, smoking).
Results: There were no significant associations between polygenic risk for any of the
psychiatric disorders tested and telomere length (p > 0.05). Antidepressant use was
significantly associated with shorter telomere length and this was independent from
a depression diagnosis or current depression severity (p ≤ 0.01). Antidepressant use
was also associated with a significantly higher risk of aging-related disease, which was
independent from depression diagnosis (p ≤ 0.05).
Conclusion: Genetic risk for psychiatric disorders is not associated with shorter
telomere length. Further studies are now needed to prospectively characterize if
antidepressant use increases risk for aging-related disease and telomere shortening,
or whether people who age faster and have aging-related diseases are just more likely
to be prescribed antidepressants.
Keywords: polygenic risk score, psychiatry, antidepressants, aging, telomeres
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INTRODUCTION
The complex and dynamic relationship between physical illness
and psychiatric disorders was highlighted in a Chief Medical
Officer’s 2013 annual report, which stated that people with a
psychiatric disorder experience worse physical health than those
without (Davies, 2014). The comorbidity of a long-term physical
illness and psychiatric disorder raises total health care costs by at
least 45% per person (Naylor et al., 2012), and increases the risk
of early mortality (Chang et al., 2011).
Psychiatric disorders such as major depressive disorder
(MDD), bipolar disorder (BD), and schizophrenia (SCZ) have
all been linked to an increased risk of severe medical conditions
throughout a person’s life (Kessler et al., 2005; Rai et al., 2014;
Kang et al., 2015; Menear et al., 2015). The prevalence of MDD
in patients with a physical illness is reported to be around
twofold to threefold higher than in the general population and
comorbid illnesses such as diabetes, pain, cancer, stroke, and
cardiovascular disease have become an increasingly important
global health issue (Kessler et al., 2005; Kang et al., 2015;
Winkler et al., 2015). A cross-sectional report on patients with
schizophrenia has stated that more than 50% of patients with
schizophrenia possess at least one comorbid physical illness such
as chronic pain, liver disease, and in particular, type-2 diabetes,
which can often lead to microvascular and macrovascular
complications such as neuropathy, coronary heart disease, and
stroke (Chwastiak et al., 2006; Meeuwisse-Pasterkamp et al.,
2008; Smith et al., 2013). BD is also associated with medical
conditions likely to increase mortality, including respiratory,
cardiovascular, and endocrine problems (Kemp et al., 2010; Forty
et al., 2014).
Interestingly, medical conditions that show the highest
prevalence of comorbidity across these three psychiatric
disorders (MDD, BD, and SCZ) tend to be associated with
aging; namely cardiovascular disease, stroke, obesity, and
type-2 diabetes. This suggests that psychiatric disorders may be
associated with faster biological aging, and some studies which
assay ‘telomeres’ support this notion (e.g., Simon et al., 2006).
Telomeres are found on the ends of chromosomes and are
special structures that are essential for protecting the chromatin
from DNA damage during recombination (de Lange, 2002).
Telomeres get shorter with each cell division as a result
of the end-replication problem and this progressive telomere
shortening is thought to represent a ‘molecular clock’ which
underlies cell aging (Blackburn, 2001; Collins and Mitchell, 2002).
Telomere shortening to a critical length, results in the realization
of the “Hayflick limit” and a reduction in the ability of cells to
divide (Blackburn, 2001). Ultimately, this means that new cells
are less able to replace old, damaged cells, and thus the body
becomes more vulnerable to aging-related diseases (Blackburn,
2001; Samani et al., 2001; Collins and Mitchell, 2002; Oh et al.,
2003; Blasco, 2005).
Shorter telomeres have been demonstrated in patients
suffering from MDD, BD, and SCZ compared to controls,
leading to speculation that telomeres may play a role in
psychiatric disorder etiology (Simon et al., 2006; Lung et al.,
2007; Kao et al., 2008; Yu et al., 2008; Hartmann et al., 2010;
Elvsåshagen et al., 2011; Wikgren et al., 2012; Lima et al.,
2015; Lindqvist et al., 2015; Mamdani et al., 2015). However,
understanding whether or not telomere shortening is directly
related to the pathophysiology of psychiatric disorders is
difficult to determine from classic case-control studies due to
confounding factors. Specifically, psychiatric patients recruited to
case-control studies are often already taking medications and are
significantly more likely to be leading unhealthy lifestyles (e.g.,
poor diet, smoking), which may impact upon rates of telomere
shortening. Subsequently, what may be more informative is
to study a known causative risk mechanism for a psychiatric
disorders and its association with telomere length, outside the
context of the disorder itself and associated environments -
polygenic risk scores (PRS) represent one option which may allow
us to achieve this.
Polygenic risk scores represent the cumulative effect of many
common risk variants for a given trait and are an effective way
of quantifying genetic risk for a psychiatric disorder, even in
non-clinical population cohorts (Sullivan, 2010; Clarke et al.,
2016). PRS have previously been used to better understand
the effect genetic risk mechanisms have on biological systems
and clinical symptoms (e.g., Alloza et al., 2017). A recent
study from our group has shown the importance of studying
genetically at-risk, but clinically unaffected individuals, when
investigating telomere length differences (Powell et al., 2017a).
We previously found that unaffected first-degree relatives
of BD patients have shorter telomeres compared to control
participants, implying an association between familial risk
for BD and shorter telomeres. This effect was not clear
amongst BD cases, potentially as a result of lithium use,
which was associated with longer telomeres within BD patients.
Subsequently, PRS allows us to draw similar comparisons in any
given population, with genetic risk being quantified empirically
using genome-wide genotype data, as opposed to familial
relatedness.
In addition to lithium use, other more commonly used
pharmacotherapies have been implicated in affecting telomere
length (Lindqvist et al., 2015; Monroy-Jaramillo et al., 2017).
Recent studies have revealed that only depressed patients
taking antidepressants have significantly shorter telomere lengths
relative to controls; with the reports surmising that the effect
is likely due to the more severe nature of depression in those
requiring medication (Lindqvist et al., 2015; Needham et al.,
2015). However, epidemiological studies independently reveal
associations between antidepressant use and an increased risk
for aging-related disease, which is irrespective of depression
diagnosis (Hippisley-Cox et al., 2001; Gareri et al., 2002; Caughey
et al., 2010). Thus, there is warrant for further investigation
on the effects of antidepressant medication on telomere length,
especially when used outside the context of depression, as this
would allow one to tease apart the impact of psychiatric diagnosis
from the impacts of medication.
Our study comprised of 351 participants from a South East
London, United Kingdom population cohort. We aimed to
investigate whether: (i) PRS for MDD, BD, or SCZ predicts
shorter relative telomere length in the non-clinical majority
of the sample; (ii) antidepressants impact on telomere length,
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irrespective of depression diagnosis, and (iii) if any significant
associations from (i) or (ii) are additionally associated with risk
for aging-related disease.
MATERIALS AND METHODS
Participants
A cohort study design was used to address the research questions.
A total of 351 participants including 167 males (mean age of 50
(16.6 S.D.)) and 184 females (mean age of 47 (14.1 S.D.)) had
their blood samples collected for DNA extraction as part of the
South East London Community Health study (SELCoH; Hatch
et al., 2011, 2016), see Table 1. Depression was the only common
clinical psychiatric diagnosis in SELCoH, based on self-report
data (n = 61). Current depression severity (at the time of blood
collection) was coded as an ordinal measure (0 = no depression
symptoms, 1 = mild depression symptoms, 2 = moderate-severe
depression symptoms), using the Clinical Interview Schedule-
Revised (CIS-R; Lewis et al., 1992), which uses an algorithm
to approximate ICD-10 diagnoses (World Health Organisation
[WHO], 1993).
To examine the relationship between PRS and telomere
length, independent from the confounders of disease factors
and medication in SELCoH, we split our sample into those
without a reported depression diagnosis (dep−), and those with
a reported depression diagnosis (dep+). DNA from participants
was extracted from blood samples and this was used to calculate
RTL and assay common genetic variation.
Ethics Statement
The SELCoH study received approval from King’s College
London research ethics committee, reference PNM/12/13-152.
TABLE 1 | The characteristics of our sample at the time of blood collection,
including gender, age, BMI, smoking status, current antidepressant use and
average polygenic risk scores (PRS), in depressed cases (Dep+) and
non-depressed controls (Dep−).
Dep− sample Dep+ sample
n 290 61
Age 48.43 (15.58) 48.36 (14.39)
Sex (% male) 142 (49) 25 (41)
BMI 27.04 (5.39) 27.99 (6.25)
Ethnicity White British: 165 White British: 35
Black Caribbean: 24 Black Caribbean: 6
Black African: 33 Black African: 3
White other: 39 White other: 12
Non-white other: 18 Non-white other: 4
Mixed: 11 Mixed: 1
Smoking (n) Never: 122 Never: 14
Current: 53 Current: 24
Ex-smoker: 115 Ex-smoker: 23
Currently taking antidepressants (n) 10 30
PRS MDD −0.0029 0.0137
PRS BD −0.0141 0.067
PRS SCZ −0.0164 0.078
Informed written consent was obtained from all participants at
the time of sample collection.
Data Availability Statement
Due to ethical restrictions SELCoH data is not publically
available. Details on the SELCoH sample and requests to
access phenotype data can be made here: http://www.slam.
nhs.uk/research/selcoh/selcoh-projects. Access to genetic data
requires local approval via the NIHR Bioresource (contact:
bioresource@kcl.ac.uk).
Aging-Related Disease
We constructed an ordinal measure for aging-related disease,
whereby 0 indicated no reported aging related disease, 1 indicated
one reported aging-related disease, and 2 indicated two or more
aging related diseases. Aging-related diseases included: type-
2 diabetes, arthritis, cardiovascular disease, stroke, high blood
pressure, and cancer.
DNA Extraction and Telomere
Assessment
10 mL of blood was collected from participants in tubes
containing EDTA (BD Vacutainer; BD, NJ, United States) and
stored at −80◦C. DNA was then extracted using a standard in-
house protocol (Freeman et al., 2003) and stored at −80◦C.
All samples had 260/280 ratios of between 1.7 and 1.9, tested
using the Nanodrop D1000 (Thermoscientific, Wilmington, DE,
United States).
To assess relative telomere length (RTL), we performed a
modified version of a quantitative polymerase reaction (qPCR)
protocol by Cawthon (2009), as previously described (Powell
et al., 2017a; Vincent et al., 2017). The protocol involves two
separate qPCRs performed on separate 384-well plates with DNA
samples pipetted into identical wells on each plate. In the first
reaction, we assayed the telomere repeat region (TTAGGG). In
the second reaction, we assayed a single copy gene, albumin,
which we used as an internal control to correct for differences
in DNA concentration between samples (Cawthon, 2009). The
telomere/albumin ratio was used to calculate RTL.
On each plate, six negative controls consisting of RNase-free
water were used to screen for any DNA contamination. An
eight-point dilution series using human leukocyte genomic
DNA (0.47, 0.94, 1.88, 3.75, 7.5, 15, 30, and 60 ng) was used on
each plate to allow for absolute quantification of each sample
and to account for any differences in efficiency between the
telomere and albumin reactions. All reactions were performed
using three technical replicates. Each qPCR mix for the telomere
reactions consisted of 10 µL of 2x qPCR Mastermix with
SYBR Green (Primer Design, Southampton, United Kingdom),
5 µL or RNase free water, 12 ng of DNA, 1000 nM of telg,
5′-ACACTAAGGTTTGGGTTTGGGTTTGGGTTTGGGTTAG
TGT-3′ and 800nM of telc, 5′-TGTTAGGTATCCCTATCCCT
ATCCCTATCCCTATCCCTAACA-3′. Four stages made up the
thermocycling conditions as follows: Stage 1: 95◦C for 15 min,
Stage 2: 2 cycles for 15 s at 94◦C and 49◦C, Stage 3: 25 cycles at
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94◦C for 15 s, 10 s at 62◦C, and 15 s at 73◦C (data collection),
Stage 4: dissociation curve (primer specificity detection).
The same reagents and quantities were used for the albumin
reactions, apart from the albumin forward and reverse primers
replaced the telomere primers. Quantities of the albumin forward
and reverse primers were adjusted to 765 nM for the forward
primer albu, 5′-CGGCGGCGGGCGGCGCGGGCTGGGCGGA
AATGCTGCACAGAATCCTT-3′ and 930 nM for the reverse
primer albd, 5′-GCCCGGCCCGCCGCGCCCGTCCCGCCGG
AAAAGCATGGTCGCCTGTT-3′. The thermocycling
conditions for the albumin reaction consisted of four stages:
Stage 1: 95◦C for 15 min, Stage 2: 2 cycles for 15 s at 94◦C and
49◦C, Stage 3: 33 cycles at 94◦C for 15 s, 10 s at 62◦C, and 15 s
at 88◦C (data collection), Stage 4: dissociation curve (primer
specificity detection).
Reactions were performed using either the ABI Prism
7900HT Sequence Detection System (Thermofisher Scientific,
MA, United States) or the QuantStudio 7 Flex Real-Time PCR
System (Thermofisher Scientific).
Genotyping and Quality Control (Target
Dataset)
DNA samples were sent to the Affymetrix Research Services
Laboratory in Santa Clara, California, CA, United States.
Genotyping for SELCoH was assayed using the United Kingdom
Biobank Axiom Array (r3) which comprises of 820,967 genetic
markers (Affymetrix, California, CA, United States). Genotype
data was put through quality control measures as outlined by
Coleman et al. (2016), using PLINK v1.07 (Purcell et al., 2007)
and mapped to genomic build hg19. Specifically, patient samples
were excluded if there was greater than 5% missingness in
genotype data, and individual SNPs were excluded if there was
greater than 5% missingness. A minor allele frequency (MAF)
threshold was set to 0.05, and a Hardy-Weinberg threshold of
0.00001, in keeping with what’s recommended for smaller sample
sizes (Coleman et al., 2016).
The absence of sample mismatching was confirmed using
sex checks, where genetic sex was compared to phenotypic sex.
The genome-wide Identity by Descent (IBD) analysis which is
performed between pairs of samples, measured the probable
number of shared alleles at any given marker, and was used
to identify and exclude relatives within our sample. Relatives
were identified as those with a PI-HAT (proportion of IBD)
threshold of greater than 0.1875; where 0.5 represents first-
degree relatives and 0.25 represents second-degree relatives. Only
a single member from each family were retained post quality
control. Following quality control, the sample consisted of 351
unrelated individuals, for which we had both genome-wide
genotype data and telomere length data.
Polygenic Risk Score Quantification
PRSice Software
Individualized Polygenic Risk Scores within our sample were
calculated using PRSice, a PRS quantification software (Euesden
et al., 2015). The software uses summary results from previously
performed, well-powered GWAS (the base dataset) to generate
PRSs in our sample, SELCoH (the target dataset). Briefly, PRSice
works by first clumping SNPs in the genotype PLINK files
corresponding to the target dataset and removing those in
high linkage disequilibrium, as this can falsely inflate polygenic
scores. Subsequently, within the target dataset the number of risk
alleles at a particular SNP is multiplied by that SNP’s effect size
(established in the base dataset), and then all the SNP information
is summed. The user can define which SNPs to include in the PRS.
For all analyses we set a p-value threshold of p = 0.1, whereby we
included all SNPs under this threshold from our base datasets to
calculate polygenic risk scores in our target dataset.
Base Datasets
The MDD base dataset (summary statistics) was obtained from
the Psychiatric Genomics Consortium (PGC) and represents
the largest GWAS for depression to-date, consisting of 135,458
MDD cases and 344,901 controls (Wray et al., 2018). The base
dataset for BD consists of GWAS results for 7,481 cases and
9,250 controls (Sklar et al., 2011). For the BD GWAS, SNP
positions were lifted over from hg18 to hg19 build using UCSC
LiftOver tool (Kuhn et al., 2013). The base dataset for SCZ
consists of insights from a multi-stage schizophrenia genome-
wide association study of up to 36,989 cases and 113,075 controls
(Ripke et al., 2014). All base datasets were downloaded from the
PGC website1.
Population Covariates
To reduce noise in our analyses as a result of ancestry
differences within the sample, we generated population covariates
(PCs) using multidimensional scaling in PLINK, via the
PRSice software, which allowed us to detect and adjust for
population structure in our analyses (Patterson et al., 2006;
Price et al., 2006). Population covariates were incrementally
tested for association via scatter charts (e.g., PC1 vs. PS2, PC2
vs. PC3, PC3 vs. PC4, etc.) until a normal distribution was
achieved. A normal distribution was achieved after the first
seven PCs, and thus this is what we used in our downstream
analyses.
Statistical Analysis
RTL Calculation
A standard deviation of less than 0.5 was required for at
least two of the three cycle threshold (Ct) technical triplicates
for a sample to be included in downstream analysis. Cq
values were then created from the remaining Ct values by
relating them to absolute quantities as part of a standard
curve. RTL was then calculated by dividing each sample’s
mean Cq value from the telomere reaction by each sample’s
mean Cq value from the albumin reaction. RTL was then log-
transformed to allow for parametric analysis. Outliers were
identified as those data points greater than two standard
deviations from the mean and subsequently removed. As a
final check, we performed a one-tailed Pearson correlation test
to confirm there was a negative correlation between log(RTL)
and age.
1http://www.med.unc.edu/pgc/results-and-downloads/results
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PRS and its Relationship to Telomere Length
(Dep−Sample Only)
To determine the effect of each PRS on telomere length
we performed three independent linear regressions, whereby
log(RTL) was selected as our outcome; age, BMI, PCs 1-7,
plate batch, smoking status (former, current, never), gender, and
ethnicity were selected as covariates; and PRS was selected as our
independent variable.
Antidepressant Use and Telomere Length (Full
Sample)
The relationship between antidepressant use and telomere length
was investigated using a linear regression, whereby log-telomere
length was selected as the outcome variable; age, BMI, PCs 1-
7, plate batch, smoking status (former, current, never), gender,
ethnicity, depression diagnosis were included as covariates; and
antidepressant use was used as our independent variable.
Antidepressant Use and Aging-Related Disease (Full
Sample)
An ordinal logistic regression was used to determine the
relationship between antidepressant use and the number of
aging-related diseases (0/1/2). Number of aging-related diseases
was selected as our outcome variable; age, BMI, PCs 1-7,
smoking status (former, current, never), gender, ethnicity, and
lifetime depression diagnosis were selected as covariates; with
antidepressant use selected as the independent variable.
Sensitivity Analyses
We performed a series of sensitivity analyses to determine
the relationship between telomere length and physical
illnesses/medication use, and the potential confounding
effects of depression severity.
Power Calculation
Power calculations indicate we have 100% power to detect small-
moderate effect sizes (effect size = 0.3) for analyses (i) to (iii),
given our sample size, with an α = 0.05.
RESULTS
Quality Control Checks
Standard curves from all reactions showed an R2 ≥ 0.98 between
quantity of known DNA and Ct values. Negative controls showed
no amplification on any of the plates and a single peak was
detected for the dissociation curves (melting curves) across all
plates, demonstrating that binding specificity of the primers to
the DNA was achieved to a high degree, see Supplementary
Information. The telomere reaction achieved a mean efficiency
of 90% and the albumin reaction achieved a mean efficiency of
79%. Efficiencies were all corrected via a standard curve on each
of the plates and all samples which didn’t pass our quality control
criteria were removed from any further analyses (17 samples).
Telomere Length and Chronological Age
A one-tailed Pearson’s correlation showed that relative telomere
length (adjusted for inter-plate variability) is negatively correlated
FIGURE 1 | Correlation between telomere length and chronological age.
A scatterplot showing a significant negative correlation between chronological
age (x-axis) and adjusted RTL (y-axis). The blue line represents a line of
best fit.
with age in our whole sample, r(351) = −0.223, p 1.20E-05
(Figure 1) as expected.
Polygenic Risk for Psychiatric Disorders
and Telomere Length
The regression model examining the effect of polygenic risk
for SCZ on log(RTL) did not reveal a significant association
(F(1,265) = 1.622, p = 0.204). Similarly, we did not find a
significant association between the polygenic risk for BD and
log(RTL; F(1,265) = 1.872, P = 0.172), nor between polygenic risk
for MDD and log(RTL; F(1,265) = 0.519, P = 0.472), see Figure 2.
The Effect of Antidepressants Use on
Telomere Length
Antidepressant use was significantly associated with telomere
length in our total sample, which was irrespective of depression
diagnosis (F(1,325) = 6.575, P = 0.011, variance explained = 2%),
see Figure 3.
Antidepressant Use and Aging Related
Disease
We found that those currently taking antidepressants also had a
higher frequency of aging-related disease, relative to those not
currently taking an antidepressant. (Estimate = −0.981 (95%
C.I. =−1.878,−0.084), p = 0.032), see Figure 4.
Sensitivity Analyses
Telomere length and Aging-Related Disease
We performed ordinal logistic regressions to determine if
log(RTL) predicts number of aging-related diseases (0,1,2) whilst
covarying for age, BMI, PCs 1-7, smoking status (former,
current, never), gender, ethnicity, lifetime depression diagnosis
and antidepressant use. Log(RTL) did not predict number of
ageing-related diseases (p > 0.05).
Telomere Length, Medication Use and Disease
We performed linear regressions which included age, sex,
ethnicity and BMI as covariates, and log(RTL) as the outcome
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FIGURE 2 | The association between polygenic risk for psychiatric disorders and telomere length. A scatter plot showing PRSs for SCZ (A, top left), BD (B, top right)
and MDD (C, bottom) adjusted for PCs 1–7 (x-axis), and log(RTL) adjusted for age, sex, ethnicity, BMI, smoking status and telomere plate batch (y-axis). The blue
line represents the line of best fit.
variable, alongside self-reported disease or medication use. No
diseases or medications predicted log(RTL), p > 0.05, see
Supplementary Information for further details.
Telomere Length, Antidepressant Use and
Aging-Related Disease
We further tested whether telomere length mediated the
association between antidepressant use and risk for aging-related
disease. So we repeated analysis (iv) as described above: An
ordinal logistic regression was used to determine the relationship
between antidepressant use and the number of aging-related
diseases (0/1/2 +; outcome variable). However, we also included
log(RTL) as a covariate. The relationship between antidepressant
use and number of aging-related diseases remained significant
(p < 0.05), suggesting the effect was not mediated by telomere
length.
Depression Severity at Blood Collection, and
Telomere Length
To confirm depression severity did not confound analyses
investigating the effects of antidepressants on log(RTL), we
repeated analysis (iii), however, we further included depression
severity (0 = none, 1 = mild, 2 = moderate/severe) as a covariate,
and found that antidepressant use still predicted log(RTL;
p < 0.05), suggesting episode severity was not confounding our
result.
DISCUSSION
Previous studies have revealed higher rates of aging-related
diseases amongst psychiatric disorder patients, with some studies
indicating that shorter telomere length (and faster aging) may
be the cause (Hippisley-Cox et al., 2001; Gareri et al., 2002;
Caughey et al., 2010). The first aim of our study was to clarify
whether genetic risk for psychiatric disorders also carries risk for
shorter telomere length. To achieve this aim we generated PRS
for MDD, BD, and SCZ, and assessed the relationship between
these PRS and telomere length measurements in a cohort of
individuals with no history of psychiatric health problems. We
found no evidence to suggest that genetic risk for psychiatric
disorders also contributes to telomere shortening, Figure 2. In
terms of translational medicine, our results suggest that although
polygenic risk scoring may be useful in predicting those at
risk for psychiatric disorders, current psychiatric polygenic risk
scores alone may not be useful in predicting those who are
also susceptible to shorter telomeres and aging-related diseases.
Instead, our results support previous work indicating the
importance of environmental factors associated with psychiatric
diagnosis, in accelerating telomere shortening (Kessler et al.,
2005; Whiteford et al., 2013).
Indeed, we found evidence that antidepressant use was
associated with shorter telomere length, an effect which was
independent of depression diagnosis. This partially corroborates
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FIGURE 3 | The association between antidepressant use and RTL. A plot
showing adjusted RTL in participants: (i) without depression and who are not
currently taking antidepressants (Dep−/Anti−), (ii) with a depression diagnosis
and who are not currently taking antidepressants (Dep+/Anti−), (iii) without
depression who are currently taking antidepressants, (iv) with depression who
are currently taking antidepressants. Participants currently taking
antidepressants had significantly shorter RTL compared to those not taking
antidepressants, irrespective of depression diagnosis. The symbol
‘∗∗’ indicates a difference of p ≤ 0.01.
previous reports which found that only depressed patients
currently taking antidepressants have shorter telomeres
(Lindqvist et al., 2015; Needham et al., 2015). However,
in contrast to previous studies which have suggested that
antidepressant use is a proxy for current depression severity, and
that this is what drives the association with shorter telomeres,
our results show that even non-depressed participants who
are taking antidepressants for other purposes (e.g., sleep) had
similarly short telomere lengths, Figure 3. We further confirmed
that current depression severity did not differ between depressed
patients who were and were not taking antidepressants at the
time of blood collection, suggesting the effect was not driven
by current depression severity. One possible explanation is that
antidepressants are increasing the proliferation of blood cells in
users, and the knock-on effect is telomere shortening. Indeed,
research using lymphoblastoid cell lines (resembling white blood
cells), hippocampal progenitor cell lines, and in vivo studies of the
hippocampus, support the notion that antidepressants increase
proliferation (Manev et al., 2001; Breitfeld et al., 2017; Powell
et al., 2017b). However, some work indicates that antidepressants
may additionally increase the activity of telomerase, which is
an enzyme involved in telomere maintenance and elongation
(Bersani et al., 2015), therefore more work is needed to better
understand the effects of antidepressants on telomere length and
proliferation over time.
Interestingly, we additionally found an association between
antidepressant use and risk for aging-related disease;
with antidepressant use predicting a higher number of
aging-related diseases, an effect which was independent of
depression case/control status, Figure 4. This matches recent
epidemiological reports that antidepressant use is associated
with an increased risk for aging-related disorders such as
cardiovascular disease (Musselman et al., 1998; Lichtman
et al., 2008; Hamer et al., 2011). Interestingly, our sensitivity
analyses suggest that the relationship between antidepressant
use and aging-related disease is not mediated by telomere
length variability, such that antidepressant use is independently
associated with both risk for aging-related disease and shorter
telomere length. These results indicate one of two things. First,
that antidepressants increase telomere shortening and risk for
aging-related disease via independent mechanisms. Second,
and more likely, that antidepressant use, or prescription, is
more common amongst those who suffer from depression (or
related conditions such as sleep problems), and who also suffer
FIGURE 4 | Antidepressant use and aging-related disease. A bar chart showing the frequency of participants with 0, 1 or 2(+) aging-related diseases, split by those
who are not currently taking antidepressants and those who are. Actual sample size within each group is shown on top of each bar. There is a significant difference in
the frequency of aging-related disease between the two groups (p < 0.05). Aging-related diseases included: type-2 diabetes, arthritis, cardiovascular disease,
stroke, high blood pressure, and cancer.
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from chronic debilitating aging-related disease. Nevertheless, the
combination of previously reported epidemiological data linking
antidepressant use with aging-related disease, and molecular data
reported here, warrants further consideration of the long-term
impact of antidepressant use on aging-related phenotypes. In
particular, studies recruiting antidepressant users (both depressed
and non-depressed) as part of a longitudinal design may help in
discerning causality.
The main limitations of our study are the small number
of individuals taking antidepressants, and the fact we may be
underpowered to detect small effect sizes. Nevertheless, our study
is the first to suggest that: (i) genetic risk for psychiatric disorders
does not predict faster biological aging, (ii) antidepressant use
is associated with shorter telomeres independently of depression
diagnosis, (iii) antidepressant use is associated with an increased
number of aging-related diseases, independently of depression
diagnosis. Our work suggests that the relationship between
antidepressant use and risk for aging-related disease may need
to be reconsidered.
CONCLUSION
We found no evidence to suggest that genetic risk for psychiatric
disorders also contribute to faster telomere shortening,
highlighting the potential importance of environmental factors
in mediating physical disease comorbidity. We did, however, find
an association between antidepressant use and telomere length,
with antidepressant use being associated with shorter telomere
length. In addition, we found antidepressant use to be associated
with a higher number of aging-related diseases in participants,
replicating previous epidemiological evidence. Further work is
now needed to test whether antidepressants induce telomere
shortening via their proliferative effects, and how antidepressant
use relates to aging-related disease.
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